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Abstract
Background: The effectiveness of intermittent preventive treatment of malaria in pregnancy (IPTp) may be compromised by
the spread of resistance to sulphadoxine/pyrimethamine (SP) across Africa. But little informtion exists on alternative drugs
for IPTp or alternative strategies for the prevention of malaria in pregnancy. Therefore, we have investigated whether
screening with a rapid diagnostic test and treatment of those who are positive (IST) at routine antenatal clinic attendances is
as effective and as safe as SP-IPTp in pregnant women.
Methods and Findings: During antenatal clinic sessions in six health facilities in Ghana held between March 2007 and
September 2007, 3333 pregnant women who satisfied inclusion criteria were randomised into three intervention arms (1)
standard SP-IPTp, (2) IST and treatment with SP or (3) IST and treatment with amodiaquine+artesunate (AQ+AS). All women
received a long-lasting insecticide treated net. Study women had a maximum of three scheduled follow-up visits following
enrolment. Haemoglobin concentration and peripheral parasitaemia were assessed between 36 and 40 weeks of gestation.
Birth weight was measured at delivery or within 72 hours for babies delivered at home. Parasite prevalence at enrolment in
primigravidae and in multigravidae was 29.6% and 10.2% respectively. At 36–40 weeks of gestation the prevalence of
asymptomatic parasitaemia was 12.1% in study women overall and was very similar in all treatment groups. The risk of third
trimester severe anaemia or low birth weight did not differ significantly between the three treatment groups regardless of
gravidity. IST with AQ+AS or SP was not inferior to SP-IPTp in reducing the risk of low birth weight (RD=-1.17[95%CI; -4.39-
1.02] for IST-SP vs. SP-IPTp and RD=0.78[95%CI; -2.11-3.68] for IST-AQAS vs. SP-IPTp); third trimester severe anaemia
(RD=0.29[95%CI; -0.69-1.30] for IST-SP vs. SP-IPTp and RD=-0.36[95%CI;-1.12-0.44] for IST-AQAS vs. SP-IPTp).
Conclusion: The results of this study suggest that in an area of moderately high malaria transmission, IST with SP or AS+AQ
may be a safe and effective strategy for the control of malaria in pregnancy. However, it is important that these encouraging
findings are confirmed in other geographical areas and that the impact of IST on placental malaria is investigated.
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Introduction
Plasmodium falciparum infection in pregnancy causes maternal
anaemia and low birth weight associated with parasitisation of the
placenta [1]. The World Health Organization recommends
intermittent preventive treatment (IPTp) with sulphadoxine-
pyrimethamine (SP), insecticide-treated bed nets (ITNs), and
effective case management as measures to protect against these
outcomes [2].
Intermittent preventive treatment linked to antenatal care will
remain an effective and sustainable strategy for the prevention of
malaria in pregnancy provided that the antimalarial drug used is
efficacious, safe, tolerable, cheap, and easy to administer,
preferably as a single dose [3]. So far SP is the only drug which
has these attributes. Thus, as resistance to SP increases and
spreads across Africa, [4,5,6] the effectiveness of the IPT strategy
may be compromised. Trials are under way to evaluate alternative
drugs that could be used for IPTp in place of SP but none of the
potential candidates have the favourable characteristics of SP
when used in areas where parasites are sensitive to this drug.
In the absence of an effective drug to replace SP for IPTp
alternative strategies for the prevention of malaria in pregnancy
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during pregnancy are beneficial to both mother and her newborn
baby [7]and so strenuous efforts are being made to increase ITNs
accessibility to pregnant women across Africa [8]. It is not clear
whether women who are protected by an ITN also need IPTp. In
a study conducted in western Kenya, the combination of IPTp and
ITNs was slightly more effective than ITNs alone (PE 56% vs.
42%) but only in primigravidae. [9]. In the Gambia, where the
prevalence of HIV infection and SP resistance are low, no
beneficial effect from SP-IPTp on anaemia or birth weight was
seen in multigravidae, with the exception of a small sub-group of
women who did not use a bed net [10].
Screening for malaria infection using a malaria rapid diagnostic
test (RDT) at scheduled antenatal clinic visits and treatment of
women who are positive with an effective antimalarial drug (IST),
combined with effective vector control, provides a potential,
alternative strategy to SP-IPTp. The WHO’s current recommen-
dation of four scheduled antenatal clinic visits, one at booking and
three subsequent visits 4 to 8 weeks apart, provides a potential
framework for implementation of an IST strategy. This strategy
may be considered in parts of Africa where resistance to SP is
increasing at alarming rates and in situations of low exposure to
malaria as in The Gambia and Zanzibar where the incidence of
malaria has gone down [11,12,13] or in Asia where transmission is
generally low [14].
Intermittent screening and treatment combined with vector
control may be an especially attractive option in such communities
where continuing use of IPTp with SP will result in a large
proportion of pregnant women receiving SP unnecessarily. This is
also the case for communities where the incidence of malaria is
highly seasonal. In these areas, many women receive IPTp during
months of the year when the risk of malaria is minimal.
Whether a screening and treatment strategy would prove to be
as effective as SP-IPTp is not known. Therefore, we have
undertaken a randomised, controlled trial in an area of Ghana
with moderate malaria transmission to determine whether IST
using SP or amodiaquine+artesunate (AQ+AS) is as effective in
preventing maternal anaemia and low birth weight as SP-IPTp.
The costs and acceptability to women and providers of such a
strategy have also been assessed.
Methods
Overall study design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. It was an individually randomised, open, controlled
trial was undertaken to investigate whether screening for malaria
with an RDT and treatment of women with a positive test with
either SP or AS+AQ was not inferior to SP-IPTp in the prevention
of anaemia in pregnancy or low birth weight.
Study population
The study was conducted in the Ejisu-Juaben and Afigya-
Sekyere East districts of the Ashanti Region of Ghana from March
2007 to September 2008. Malaria transmission in this area is
perennial but with a peak in the rainy season. The predominant
parasite is P. falciparum. The entomological inoculation rate in the
neighbouring area of Kintampo is about 250 infectious bites per
year. HIV prevalence in Ashanti region is reported to be 3.0% and
2.2% in the general population and in pregnant women
respectively (Ghana Health Service 2007 Annual Report).
Enrolment was undertaken at the antenatal clinic of three
district hospitals and three health centres in the study area. The
study population comprised pregnant women of all parities who
presented at the antenatal clinics with a gestational age of 16 to 24
weeks at their first booking. Women who were temporary
residents, had had a prior dose of SP-IPTp, had a haemoglobin
concentration ,5 g/dl, gave a history of sensitivity to SP,
amodiaquine or an artemisinin, had an illness requiring hospital
admission or declined to join the trial were excluded (Figure 1).
Ethics
The study protocol was approved by the ethics committee of the
London School of Hygiene and Tropical Medicine and the
Committee on Human Research and Publications Ethics of the
School of Medical Sciences, Kumasi – Ghana. A Data, Safety and
Monitoring Board (DSMB) approved the protocol, standard
operating procedures and analysis plan.
Sample size
Sample size was calculated on the assumption that the
prevalence of moderately severe anaemia (Hb,8 g/dl) in the
third trimester of pregnancy and of low birth weight in women in
the SP-IPTp arm of the study would be at least 12% and 6%
respectively, figures based on findings from a study undertaken in
The Gambia [15]. To establish that IST was not inferior to SP-
IPTp we decided that it was necessary to show that the differences
in the percentages of women with moderately severe third
trimester anaemia or low birth weight between the IST groups
and the SP-IPTp group should not be more than 5% or 4%
respectively, differences that would be clinically important. To
meet these criteria with 90% statistical power and allowing for
20% loss to follow-up it was calculated that 1,110 women were
needed in each study arm to give a total sample size of 3,330.
Procedures
After written informed consent had been obtained, eligible
women of all parities were randomised to one of the three
treatment groups described above. Women who declined to
participate were given SP-IPTp according to the national
guidelines. The following process was followed to randomise
women into the study arms. A list of random numbers was
computer generated as identification numbers, randomly allocated
to treatment groups and grouped in blocks of 15 by an IT
specialist who did not participate further in the study. The list of
identification numbers with their corresponding treatment groups
was printed and cut into slips. Fifteen slips each with an
identification number and an allocated treatment group were
sealed in an envelope. During enrolment an eligible pregnant
woman was asked by the recruitment team to pick a slip from the
sealed envelope. The allocated treatment group printed on each
slip indicated which treatment arm the women belonged to and
the corresponding identification number was used to identify her.
This constituted entering the study, and treatment group
allocation was binding on the recruiting team and the woman
from this point. Another envelope was opened only when the
contents of the previous one had been exhausted. The PI and all
other project staff were blinded to the randomisation process and
treatment allocation.
At enrolment, a finger prick blood sample was obtained for
measurement of haemoglobin concentration, preparation of thin
and thick blood films for malaria parasite counts and preparation
of a filter paper blood spot. During the last 3 months of the trial,
women in treatment group 1 who had a positive blood film and
received SP-IPTp were seen again on day 14 and day 28 after
treatment and a further blood film and blood spot obtained to
check on the response to treatment with SP. HIV screening was
IST versus IPT in Pregnancy
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antenatal services recommended in Ghana with an option for
treatment but the results of HIV screening were not available to
the investigators. Women in the SP-IPTp arm received an initial
dose of SP (1500 mg sulphadoxine/75 mg pyrimethamine) as a
single dose. Pregnant women in treatment groups 2 and 3 were
screened for malaria infection with an OptiMALH dipstick, a
lactate dehydrogenase (LDH) based RDT. The OptiMALH
dipsticks were purchased from DiaMed AG, Cressier, Switzerland
who supplied and organised transportation to the study site in
batches as and when needed,. The test kits were kept at room
temperature always at the study site. The viability of the kits were
tested monthly throughout the study period using positive test
controls obtained from the manufacturer. The tests were
performed and interpreted by the study team following the
manufacturer’s instructions. Women in treatment group 2 were
treated with a single dose of SP (1500 mg sulphadoxine/75 mg
pyrimethamine) if the RDT was positive. Women in treatment
group 3 were treated with AQ+AS (AQ-300 mg + AS-100 mg
twice daily for 3 days) if the RDT was positive. All treatments with
SP and the first dose of AQ+AS treatment were administered by a
member of the study team but doses 2 and 3 of AQ+AS were given
to study women to take at home unsupervised. Women in groups 2
and 3 received no antimalarial treatment or IPT if their RDT
results were negative. All women received a daily supplement of
ferrous sulphate (200 mg) and folic acid (4 mg) tablets as part of
the routine antenatal care services provided in Ghana throughout
the study period. SP was purchased from Kinapharma Ltd, Ghana
and AQ+AS was provided by the Ministry of Health, Ghana. All
study women received a long-lasting insecticide treated bed net
(LLIN) and instructions on how to use this at enrolment.
Study women were asked to attend for follow-up antenatal care
and IPTp or screening at 24, 32 and 36 weeks of gestation. At the
24 and 32 week visits, women in treatment group 1 received SP-
IPTp whilst women in treatment groups 2 and 3 were screened
with the RDT and, if positive, treated with SP or AS+AQ
according to the allocation arm. As part of safety assessment, all
women were visited at home by a trained community health
worker to record any complaints that the women might have seven
days after each scheduled antenatal visit.
Figure 1. CONSORT chart showing enrolment and follow-up status of women in each study arm.
doi:10.1371/journal.pone.0014425.g001
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and 40 weeks of gestation (before delivery) for determination of
haemoglobin concentration and for preparation of thin and thick
blood films. However, the smears were read retrospectively and so
the results were not available for the point of care. Any study
woman who presented with a history of fever or other features
suggestive of malaria between scheduled antenatal visits was
screened for malaria using an RDT and treated with quinine
(30 mg/kg in divided doses daily for 5 days) regardless of
treatment group.
Information on the outcome of pregnancy was obtained for
2706 of the 3333 study women (81.2%), 2144 of whom delivered
at a health centre or hospital and 562 at home. If a woman
delivered at a health facility, birth weight was recorded by a
midwife who was unaware of the treatment group of the woman
who she was attending. Women who delivered at home were
traced through a network of trained community health workers
within 72 hours of delivery and the infant’s weight was measured
at home. The occurrence of miscarriages, still births, neonatal
deaths and the presence of congenital abnormalities was recorded
by midwives. If any congenital abnormality was suspected, a full
examination, including a neurological assessment, was undertaken
by a qualified medical doctor. Field teams visited all women and
babies at approximately 6 weeks post delivery to obtain reports of
any neonatal adverse events and a blood film was obtained from
mothers at this time. We could not determine the prevalence of
placenta malaria and efficacy of SP in postpartum study women as
proposed due respectively to inadequate funding and difficulty in
finding postpartum women with parasitaemia.
An experienced microscopist, unaware of treatment group
assignment, read all the blood films and quantified parasitaemia
against 200 leucocytes in thick blood smears. A thick blood film
was declared negative only after examination of 100 high power
fields (HPF). An independent expert microscopist from the
Noguchi Memorial Institute of Medical Research read ten percent
of all blood slides obtained at enrolment and on follow up visits for
quality assurance. Agreement between the study microscopist and
the reference microscopist was 91.7% and a kappa of 0.83.
Haemoglobin (Hb) concentration was measured using Hb 301
Hemocues (HemoCue AB, Angelholm, Sweden). Paired samples
from women who failed treatment with SP were tested for
molecular markers to differentiate reinfections from recrudescenc-
es using genetic markers as described previously [16]. HIV testing
was not part of the study but it is likely that some HIV positive
may have been included in the sample.
Statistical methods
Stata version 10 (StataCorp, College Station, Texas) was used
for data analyses. The primary objective of the study was to
demonstrate that the risk of third trimester moderately severe
anaemia (Hb,8 g/dl) in the IST groups was no more than 5%
greater than in the SP-IPTp arm. Secondary objectives were to
demonstrate that the risks of low birth weight (BW,2500 g),
spontaneous abortions, intrauterine deaths/stillbirths, neonatal
and maternal mortality were not more than 4% higher in women
in the IST groups than in women who received SP-IPTp. The
principal analysis of primary and secondary outcomes was per
protocol but an "intention-to-treat" analysis was also undertaken
according to a statistical analysis plan approved by the Data and
Safety Monitoring Board. In the per protocol analysis, only data
from women who remained within their randomization group,
received two courses of SP-IPTp (Group 1) or were screened twice
using an RDT at scheduled visits (groups 2 and 3) and in whom
the primary outcome had been recorded were considered for
analysis. In the intent-to-treat analysis, women were included if
they had received an initial treatment of IPTp or had had an initial
screening test done and provided that an outcome had been
recorded.
The proportion of the per protocol and intention-to-treat
populations experiencing each primary and secondary outcome
for the treatment groups, and the associated 2-sided 95% CI for
the difference, was estimated using the generalized linear model.
To declare non-inferiority with a significance level of 0.05%, the
upper boundary of the 2-sided 95% CI for the estimated treatment
effect (risk difference) had to be below the pre-defined non-
inferiority margins (D) of 5% and 4% for third trimester severe
anaemia and low birth weight respectively. We controlled for
gestational age at enrolment, gravidity, baseline parasitaemia and
anaemia using binomial regression.
Results
Baseline demographic and clinical characteristics
A total of 3333 of the 3472 potentially eligible pregnant women
who were screened (96%) were enrolled into one of the three
treatment groups (Figure 1). At the end of follow up, 2674 (80.2%)
evaluable records for third trimester haemoglobin concentration
and 2675 (80.2%) records for birth weight were available.
Baseline characteristics of women in the three treatment groups
were very similar at enrolment (Table 1). In all three treatment
groups, more than half of the women were aged between 20 and
30 years with an overall mean age of 26.6 years. About ninety
percent of the women had received a formal education, mainly up
to secondary school level (70%). Fifty percent of the study
population households already owned a bed net. Twenty-three
percent of women were primigravidae and twenty-three percent
were secundigravidae. About 4% of women had a haemoglobin
concentration below 8 g/dl; the mean Hb overall was 10.97 g/dl.
Anaemia at enrolment was associated significantly with asymp-
tomatic malaria parasitaemia (p,0.05). The prevalence of malaria
infection on presentation at the antenatal clinic in women in the
SP-IST and AQAS-IST groups as determined by the OptiMALH
RDT was 22.9% (RDTs were not done in women in the SP-IPTp
group). Asymptomatic parasitaemia as determined by microscopy
was present in 16.3% of study women overall with parasite
densities less than 1000/mL in 99% of them. P. falciparum was the
most prevalent malaria species. P. malariae and P.ovale were also
detected but only few women (,3%) carried these species.
Additional blood samples were obtained 14 and 28 days after
administration of a first dose of SPI-IPTp from 71 women who
were parasitaemic on presentation. Eleven (15.5%; 95% CI 7.9%-
26.0%) were positive by day 28. PCR corrected parasitological
failure on day 28 was 5.6% (95% CI 1.6%-13.8%). The overall
prevalence of HIV in pregnant women who agreed to screening in
the study clinics during the period of the trial was approximately
1.5%.
Study outcomes – per protocol analysis
At 36–40 weeks of gestation (before delivery) the prevalence of
severe anaemia (Hb,8 g/dl) and moderate (8,=Hb,11 g/dl)
anaemia was respectively 1.7% and 45.9% overall and was similar
in all treatment groups; similarly asymptomatic parasitaemia was
12.0% in study women overall and was very similar in all
treatment groups. The mean Hb concentration of all women
between 36 and 40 weeks of gestation was 11.0 g/dl and was
similar in all the groups. Generally, there was a significant increase
in mean Hb concentration of 0.29 g/dl at 36–40 weeks gestation
over the baseline Hb concentration (Figure 2). The increase was
IST versus IPT in Pregnancy
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compared to non-parasitic women (0.21 g/dl) but there was no
significant difference in the increase in haemoglobin concentration
during the course of pregnancy between the three treatment
groups. The overall prevalence of low birth weight was 11.0% in
the study women and did not differ significantly among the study
groups (Table 2).
The risk of anaemia (severe or moderate) did not differ
significantly between the three treatment groups across gravidity
(Table 3). It was no higher in the IST groups than in women who
Table 1. Comparison of demographic and baseline characteristics of study women.
SP-IPTp IST-SP IST-AQAS Total
(N=1111) (N=1112) (N=1110) (N=3333)
n (%) n (%) n (%) n (%)
Age [years] Q
,20 107 9.8 113 10.4 107 9.8 327 10.0
20–24 326 30.0 321 29.5 351 32.2 998 30.5
25–29 336 30.9 324 29.7 303 27.8 963 29.5
30+ 318 29.3 332 30.5 330 30.3 980 30.0
Mean (SD) 26.5 5.9 26.6 6.0 26.5 6.0 26.6 6.0
Median (IQR) 26 8 26 8 26 8 26 8
Educational level reached
None 72 9.1 90 11.2 87 10.7 249 10.3
Primary 145 18.3 132 16.4 135 16.6 412 17.1
Junior secondary school 489 61.7 511 63.3 485 59.6 1485 61.5
Senior secondary school 75 9.5 50 6.2 85 10.4 210 8.7
Tertiary 12 1.5 24 3.0 22 2.7 58 2.4
Occupation
Farmer 95 12.1 106 13.2 104 12.9 305 12.7
Housewife 137 17.4 127 15.8 120 14.9 384 16.0
Salary Worker 356 45.2 352 43.8 375 46.5 375 45.2
Trader 29 3.7 38 4.7 39 4.8 39 4.4
Other 171 21.7 181 22.5 168 20.8 168 20.8
Households with a bed net
No 477 47.9 464 45.8 507 50.1 1448 47.9
Yes 518 52.1 550 54.2 505 49.9 1573 52.1
Sleep under net last night
No 221 27.6 241 30.0 235 29.6 697 29.1
Yes 580 72.4 563 70.0 558 70.4 1701 70.9
Gravidity
3 or above 618 55.7 588 53.0 606 54.7 1812 54.5
2 246 22.2 276 24.9 244 22.0 766 23.0
1 245 22.1 246 22.2 258 23.1 749 22.5
Haemoglobin (g/dl)
,8 35 3.2 38 3.4 47 4.2 120 3.6
8–10.9 564 50.7 597 53.7 595 53.6 1756 52.7
11 or above 512 46.1 477 42.9 468 42.2 1457 43.7
Mean (SD) 10.7 1.4 10.6 1.4 10.6 1.4 10.6 1.4
Median (IQR) 10.8 1.7 10.7 1.9 10.7 1.9 10.7 1.9
Baseline Parasitaemia
No 926 83.5 925 83.3 937 84.5 2788 83.8
Yes 183 16.5 186 16.7 172 15.5 541 16.3
Geometric mean 198 10.2 197 10.8 187 10.7 582 10.5
parasite density
doi:10.1371/journal.pone.0014425.t001
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vs. SP-IPTp and RD=-0.36 [95% CI;-1.12-0.44] for IST-AQAS
vs. SP-IPTp). The upper boundaries of the 2-sided 95% CI for the
risk differences estimated between SP-IPTp and the IST groups
were below the non-inferiority margin of 5% for third trimester
severe anaemia, the main trial endpoint (Figure 3A). Third
trimester severe anaemia, the primary trial end-point, was
associated significantly in a univariate analysis with baseline
parasitaemia baseline anaemia and young maternal age (p,0.05)
(Table 3). In a multivariate analysis, which adjusted for the
number of visits made by a woman, weeks of gestation at
enrolment, gravidity and treatment group, third trimester severe
anaemia remained significantly associated with baseline anaemia
(p,0.0001) and young maternal age (p=0.02) but only marginally
with baseline parasitaemia (p=0.07) (Table 3).
Similarly, the risk of low birth weight did not differ
significantly between the three treatment groups regardless of
gravidity; (RD=-1.17 [95% CI; -4.39-1.02] for IST-SP vs. SP-
IPTp and RD=0.78 [95% CI; -2.11-3.68] for IST-AQAS vs.
SP-IPTp). The upper boundaries of the 2-sided 95% CI for the
risk differences estimated between women in the SP-IPTp group
and the IST lie below the non-inferiority margin of 4% set for
low birth weight (Figure 3B). In a univariate analysis, low birth
weight was associated significantly with baseline parasitaemia,
low gravidity and young maternal age (p,0.05). However, in a
multivariate analysis, which adjusted for the number of visits
made by a woman, weeks of gestation at enrolment, gravidity
and treatment group, only gravidity remained significantly
associated with low birth weight. Primigravidae (RR=2.10;
95%CI 1.49-2.95; p,0.0001) and secundigravidae (RR=1.76;
95% CI 1.28-2.43; p=0.001) were more likely to deliver low
birth weight babies compared to multigravidae regardless of
intervention arm. But the risk of low birth weight did not differ
significantly between the three treatment groups across gravidity
(Table 4).
One hundred and forty-seven episodes of illness associated with
malaria parasitaemia were recorded among study women between
scheduled antenatal clinic visits; 44, 51 and 52 of these were in SP-
IPTp, IST with SP, and IST with AS+ AQ groups respectively.
The differences in the illness episodes are not statistically
significant.
In all 2211 RDT tests were done in women in treatment groups
2 and 3 respectively of which 23% and 23% were positive and led
to treatment. The risk of third trimester severe anaemia and low
birth weight in those who were RDT negative throughout
pregnancy and did not receive antimalarial treatment were no
higher than in the SP-IPT arm. But the risk of parasitaemia at 36–
40 weeks was higher in the SP-IPT arm than in the screening and
treatment arms (Supplementary Table S1).
There were no statistically significant differences in the risk of
preterm deliveries, abortions or perinatal births between the
treatment groups (Supplementary Table S2). There were no
maternal deaths. The proportion of women who reported adverse
events during the 7 days following administration of SP-IPTp or
following treatment with SP or AS+AQ did not differ significantly
between the treatment groups with the exception of a complaint of
general weakness (Supplementary Table S3) which was reported
slightly more frequent in the group who received treatment with
AS+AQ compared to the SP-IPT group (33.8% vs. 29.1%;
p=0.04).
Study outcomes – intention to treat analysis
All primary and secondary outcomes were also analysed by
intention to treat analysis and the results were very similar to those
presented above (supplementary tables provided). Supplementary
Table S4 show the comparison of key outcomes in women
Figure 2. Mean change in Hb concentrations at 36 weeks gestation over baseline.
doi:10.1371/journal.pone.0014425.g002
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third trimester severe anaemia and low birth weight are shown in
supplementary Tables S5 and S6 respectively.
Discussion
This study has shown that IST, using either SP or AS + AQ,
was not inferior to IPTp with SP in preventing maternal anaemia
and low birth weight, according to the non-inferiority criteria that
were set prior to the trial, in women who used an LLIN in an area
of moderately high malaria transmission in Ghana. There are a
number of possible reasons why IST performed as well as SP-IPTp
in our study. Firstly, it is possible that malaria is not an important
cause of anaemia or low birth weight in the study area, in which
case it would be difficult to detect an impact of different control
strategies on the prevalence of these complications of malaria in
pregnancy unless a much larger trial than the one we did was
undertaken. We think that this is an unlikely explanation for our
findings for several reasons. The study area is one of derived forest
with perennial malaria transmission, although with a pronounced
seasonal peak. The entomological inoculation rate in the
neighbouring area of Kintampo was recently estimated to be
267 infective bites per year [17] and the prevalence of
parasitaemia on presentation at the antenatal clinic among study
women was 29.6% and 10.2% in primigravidae and in
multigravidae respectively. These findings suggest that pregnant
women in the study area are still being moderately exposed to
malaria and that the level of transmission in the study area is
comparable to that seen in communities where SP-IPT has been
shown previously to have a significant impact [18,19]. Further-
more we found an association between anaemia and malaria
parasitaemia on presentation. A second possible explanation for
our findings is that SP is no longer effective in the study area which
would again make any comparisons between IST with SP and SP-
IPTp unhelpful. In these circumstances, IST with AS+AQ would
have been expected to show a better response than either IST or
IPTp with SP and this was not the case. Furthermore, the
adequate parasite clearance rate at day 28 in women who received
a single dose of SP-IPTp was 85% (uncorrected) indicating only a
moderate level of SP resistance. In an additional study carried out
in the study area six months after completion of the study, the
adequate parasite clearance rate by day 42 in 109 women was also
85% (unpublished data). Thus, it seems likely that IST with SP or
AS+AQ can be as effective as SP-IPTp with the same drug in an
area with moderate malaria transmission, marked seasonality and
moderate SP resistance.
Demonstration of efficacy is only one aspect of the evaluation of
a potentially new control tool; other important aspects are the ease
with which it could be implemented, its acceptability and its cost.
These aspects of IST have been evaluated in the current study and
compared with those of SP-IPTp. The results of these studies will
be presented in detail elsewhere. However, preliminary analysis of
the findings studies indicates that IST can be introduced into a
busy, antenatal clinic without disrupting its function. The
Table 2. Comparison
a of key outcomes in women enrolled in SP-IPTp or IST groups.
SP-IPTp IST-SP IST-AQAS Total
n % n % p-value
b n % p-value n %
Haemoglobin
c
Hb,8 g/dl 12 1.4 15 1.7 0.65 15 1.7 0.74 42 1.6
8,=Hb,11 g/dl 413 46.9 398 45.1 398 45.6 1,209 45.9
Hb.=11 g/dl 455 51.7 470 53.2 459 52.6 1,384 52.5
Mean (sd) 11.03 1.3 10.98 1.2 0.29 11.02 1.3 0.92 11.01 1.2
Median (interquartile range) 11 1.6 11 1.5 11.1 1.6 11 1.5
Birth weight
d
BW=.2.5 Kg 776 89.3 779 90.3 0.41 745 87.3 0.25 2,300 89.0
BW,2.5 Kg 93 10.7 84 9.7 108 12.7 285 11.0
Mean (sd) 3 0.5 3.02 0.5 0.43 2.98 0.4 0.06 3 0.5
Median (interquartile range) 2.98 0.6 3 0.6 2.98 0.6 3 0.6
Parasitaemia prevalence
e
Yes 77 12.3 79 12.4 0.59 74 11.3 0.97 230 12.0
No 549 87.7 560 87.6 580 88.7 1,689 88.0
GMPD 79 8.4 86 8.6 80 7.1 245 8.0
NOTE. Data are the number and percentage of women assessed at 36 to 40 weeks of gestation (haemoglobin & parasitaemia) and at delivery (birth weight), unless
otherwise indicated.
SP-IPTp: intermittent preventive treatment with SP.
IST-SP: intermittent screening and treatment with SP.
IST-AQAS: intermittent screening and treatment with amodiaquine plus artesunate combination.
GMPD; geometric mean of parasite density.
aComparison was restricted to only women who remained within their randomization group, received two courses of SP-IPTp (IPT group) or were screened twice using
an RDT at scheduled visits (IST groups) and in whom the primary outcome had been recorded.
bp,0.05 means observed differences between comparison groups is statistically significant or not significant if P.0.05.
cFor this comparison of SP-IPT, SP-IST and AQAS-IST arms included 880, 883 and 872 women respectively.
dFor this comparison of SP-IPT, SP-IST and AQAS-IST arms included 869, 863 and 853 women respectively.
eFor this comparison of SP-IPT, SP-IST and AQAS-IST arms included 626, 639 and 654 women respectively.
doi:10.1371/journal.pone.0014425.t002
IST versus IPT in Pregnancy
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14425approach appears acceptable to women who are used to receiving
IPT with SP provided that the rationale for the intervention is
explained to them [20].
Available evidence suggests that RDTs detect circulating
parasite antigen and so compared to microscopy are better at
detecting sub microscopic parasitaemia and may be a reliable
indicator of placental infections [21]. An IST strategy draws on
this and is heavily dependent upon the sensitivity and specificity of
the RDT used to detect malaria infection. However, it is uncertain
which kind of RDT would be most appropriate for diagnosing
malaria in pregnancy. In general, assays based on HRP2 are
considered more sensitive and more thermostable than those based
on LDH and a sensitive test may be needed to detect parasites in
the placenta. On the other hand HRP2 may persist in the
circulation for several weeks after parasites have disappeared so
that there is a danger that using an HRP2 test for repeated
screening may result in women being treated unnecessarily when
they attend for their next scheduled screening if they have been
treated for an infection a month previously. Conversely a relatively
insensitive test may not be able to detect an infection confined
largely to the placenta. Few studies [21,22,23,24] have reported
good accuracy of RDTs used in the diagnoses of malaria in
peripheral and placenta blood at delivery. However, studies of
diagnostic accuracy in pregnant women attending antenatal clinics
[25,26,27] are scarce and report a range of sentivities. In this study
we found that the sensitivity and specificity of the OptiMAL test
were 93.8% and 81% respectively compared to microscopy. A
large study conducted by the WHO, with collaboration from
FIND and CDC, has recently assessed the performance of about
40 commercially available RDTs in terms of their sensitivity,
thermostability and ease of use [28]. This study is timely and will
guide the choice of malaria RDTs in varying situations but more
work is needed on defining the optimum test for detection of
malaria in pregnancy.
No difference was found between the prevalence of peripheral
blood parasitaemia between the treatment groups at 36–40 weeks
of pregnancy or at six weeks post partum but the possibility that
IST with SP or AS+AQ is not as effective as IPT with SP in
preventing infection of the placenta cannot be excluded. This
study had only limited financial resources which precluded
analysis of the impact of each of the study interventions on the
prevalence of placental malaria as measured by histology. How
important such a difference might be in the absence of any
apparent clinical adverse effects is uncertain but this needs to be
investigated. Other weaknesses of this study are the absence of
linked data on HIV positivity, although it is known that the overall
prevalence of HIV positivity in the study population is relatively
low, approximately 1.5% in the study clinics.
We are confident that the major finding of this study that IST is
not inferior to SP-IPTp in the prevention of anaemia in pregnancy
and low birth weight is sound and that IST is a potentially
promising strategy for the control of malaria in pregnancy,
especially in areas where the incidence of malaria is decreasing or
where malaria is very seasonal. However, it is important that these
encouraging findings including birth outcomes and maternal
morbidity findings are confirmed in other geographical areas
including parts of eastern and southern Africa, where SP is now
failing since we have no alternative drug yet for SP and because
the next generation of potential drugs are less likely to fulfill the
same favourable profile of SP. As part of these it is also important
that the impact of IST on placental malaria is investigated. A
large multicentre trial of IST (clinicaltrials.gov identifier:
Table 3. Factors associated with third trimester severe anaemia in study women.
3rd trimester severe
anaemia Unadjusted RR (95%CI) p-valuea Adjusted RRb (95%CI) p-value
Nn %
Treatment group
SP-IPT 880 12 1.36 1.00 1.00
IST-SP 883 15 1.7 1.25 (0.59–2.65) 0.57 1.31 (0.63–2.75) 0.45
AQAS-IST 872 15 1.72 1.26 (0.59–2.68) 0.55 1.15 (0.54–2.44) 0.72
Gravidity
Multigravidae 1,461 19 1.3 1.00 1.00
Secundigravidae 590 9 1.53 1.17 (0.53–2.58) 0.69 0.49 (0.20–1.18) 0.11
Primigravidae 579 14 2.42 1.86 (0.94–3.68) 0.08 0.53 (0.23–1.24) 0.14
Baseline parasitaemia
No 2,234 28 1.25 1.00 1.00
Yes 398 14 3.52 2.81 (1.49 5.28) 0.001 1.90 (0.95–3.77) 0.07
Baseline severe anaemia
No 2,545 30 1.18 1.00 1.00
Yes 90 12 13.33 11.31 (5.99–21.36) ,0.001 7.74 (3.76–15.92) ,0.001
Age category
.=30 years 804 7 0.87 1.00 1.00
25–29 years 786 8 1.02 1.17 (0.42–3.21) 0.76 1.32 (0.48–3.66) 0.594
,=24 years 993 26 2.62 3.01 (1.31–6.89) 0.01 3.29 (1.25–8.65) 0.02
RR: risk ratio; CI: confidence interval; IPT: intermittent preventive treatment; IST: intermittent screening and treatment.
ap,0.05 means observed differences between comparison groups is statistically significant or not significant if P.0.05.
bRRs were modeled using binomial regression. Treatment group, gravity, baseline parasitaemia and severe anaemia, and age category were included final model.
doi:10.1371/journal.pone.0014425.t003
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Low birth weight Unadjusted RR (95%CI) p-valueh Adjusted RRi (95%CI) p-value
Nn %
Treatment group
SP-IPT 868 92 10.6 1.00 1.00
IST-SP 860 81 9.42 0.89 (0.67–1.18) 0.41 0.87 (0.65–1.15) 0.32
AQAS-IST 850 105 12.35 1.17 (0.89–1.52) 0.26 1.16 (0.89–1.51) 0.26
Gravidity
Multigravidae 1,420 109 7.68 1.00 1.00
Secundigravidae 581 75 12.91 1.68 (1.27–2.22) ,0.001 1.76 (1.28–2.43) 0.001
Primigravidae 572 94 16.43 2.14 (1.65–2.77) ,0.001 2.10 (1.49–2.95) ,0.001
Baseline parasitaemia
No 2,175 219 10.07 1.00 1.00
Yes 400 59 14.75 1.46 (1.12–1.91) 0.01 1.25 (0.94–1.65) 0.12
Baseline severe anaemia
No 2,489 268 10.77 1.00 1.00
Yes 89 10 11.24 1.04 (0.57–1.89) 0.89 0.82 (0.45–1.48) 0.51
Age category
.=30 years 771 67 8.69 1.00 1.00
25–29 years 996 115 11.55 1.07 (0.78–1.47) 0.68 0.86 (0.61–1.20) 0.37
,=24 years 767 92 11.99 1.57 (1.19–2.07) ,0.001 0.93 (0.65–1.33) 0.7
RR: risk ratio; CI: confidence interval; IPT: intermittent preventive treatment; IST: intermittent screening and treatment.
hp,0.05 means observed differences between comparison groups is statistically significant or not significant if P.0.05.
iRRs were modeled using binomial regression. Treatment group, gravity, baseline parasitaemia and severe anaemia, and age category were included final model.
doi:10.1371/journal.pone.0014425.t004
Figure 3. The effect of IST with AS + AS or SP compared with SP-IPTp on the risk of third trimester severe anaemia (panel A) or low
birth weight (panel B) in women who received these interventions. The error bars shown indicate 2-sided 95% confidence intervals (CIs). The
areas bound by 25 to 5 (panel 3A) and 24 to 4 (panel 3B) indicate zone of non-inferiority. In both panels the CIs lie to the left of the upper
boundaries of the CIs and include zero indicating IST is non-inferior to SP-IPTp.
doi:10.1371/journal.pone.0014425.g003
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malaria transmission is markedly seasonal will address these issues.
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